Purification of chemicals from urine as anticancer agents was initiated by Dr. S. R. Burzynski as early as 1973 in Texas, USA. Those preparations are for the treatment of terminal cancer patients. Clinical results were encouraging. Basic research was actively pursued by DR. M. C. Liau of Burzynski Research Institute, who was instrumental in the elucidation of basic mechanisms of differentiation therapy mediated by urinary chemicals. It was discovered by this pioneering group that one of the urinary chemicals, namely phenylacetate, was effective in the treatment of brain tumors. This was a great discovery, beacuse there were no effective drugs that could cross blood brain barrier. Phenylacetate was quickly approved by FDA, and was now in phase II clinical trial conducted by NCI. which confirmed that phenylactate was effective and nontoxic against brain tumors.
Dr M. C. Liau, a Baylor College of Medicine educated biochemist, set foot in China in 1995 to initiate purification of anticancer chemicals from urine, which led to the products called CDA-II as parenteral and capsule preparations. Phase I clinical trials began in Sept., 1995 at the First Affiliated Hospital of Anhui Medical University, and in June, 1996 at the Sano Surgical Hospital of Japan. These preparations have been tested on 47 cases in China and 50 cases in Japan, all of them terminal cases of solid cancers. Results were astonishingly successful. Around 70% responded to the treatment. Best yet, there were little adverse effects, except for the venous irritation at the injection site. It appears then that differentiation therapy is on the horizon, and it is going to become a therapy of choice for cancer.
Although urine therapy has a great potential, it has limitation too. The problem of contamination, and the problem of too little effective ingredients set a limitation of urine consumption to cancer therapy. A bottle of 100c.c. CDA-II injection is purified from 7000cc urine, and one 0.5g capsule represents effective ingredients from 700cc urine. For therapeutic purpose, a patient needs two bottles of CDA-II injection, or 20 capsules a day. This can only be achieved by purified preparations. It is not possible to rely on drinking urine to reach therapeutic dosage. Cell differentiation inducing chemicals in the urine were purified by modern technology to make CDA-II preparations. These were highly concentrated effective ingredients. As clinical trials have demonstrated, these preparation were effective and without serious adverse effects.
CDA-II preparations are intended for the treatment of cancer. While on cancer clinical trials, data have emerged to indicate that CDA-II preparations were surprisingly effective in reducing blood sugar and blood pressure, for rheumatalgia, to increase appetite and energy, and in improvement on complexion to look young and beautiful. It appears that CDA-II has retained most benefits attributable to urine therapy, and without bad sides associated with the urine therapy. We are paying attention to monitor effects on other chronic symptoms.
Because of the success of CDA-II in clinical trials, the superiority of differentiation therapy over conventional cytotoxic therapy is readily evident. It is more effective, and nontoxic. It is also effective against cancers totally unresponsive to cytotoxic therapy, such as hepatoma, carcinoma of the pancreas, brain tumors, etc. CDA-II becomes the only hope for many desperate cancer patients. People are anxious to know where to get CDA-II. Those who know the benefit of urine therapy, but dare not to try, may consider taking CDA-II capsule instead. Chinese Association of Urine Therapy will be pleased to help those in need of CDA-II. Please get in touch with the Association.